Simone Varca

Rome, 00168, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Feasibility and Compliance of Stool Collection for Future Microbiome-Based Colorectal Cancer Screening: Preliminary Findings from a Prospective Multicenter FIT-Positive Cohort.

Feasibility and Compliance of Stool Collection for Future Microbiome-Based Colorectal Cancer Screening: Preliminary Findings from a Prospective Multicenter FIT-Positive Cohort.

Journal: Microorganisms

Published: June 08, 2026

Letter: Peripheral Blood Eosinophils as Complementary Biomarkers for Diagnosis and Follow-Up in Eosinophilic Oesophagitis.

Letter: Peripheral Blood Eosinophils as Complementary Biomarkers for Diagnosis and Follow-Up in Eosinophilic Oesophagitis.

Journal: Alimentary pharmacology & therapeutics

Published: June 05, 2026

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

E-Gastryal® + Magnesium Alginate Plus PPI vs. PPI Alone in GERD: Results from the GENYAL® Randomized Controlled Trial.

E-Gastryal® + Magnesium Alginate Plus PPI vs. PPI Alone in GERD: Results from the GENYAL® Randomized Controlled Trial.

Journal: Journal of clinical medicine

Published: May 10, 2025

The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects.

The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects.

Journal: Biomedicines

Published: December 21, 2024

Exploring novel circulating biomarkers for liver cancer through extracellular vesicle characterization with infrared spectroscopy and plasmonics.

Exploring novel circulating biomarkers for liver cancer through extracellular vesicle characterization with infrared spectroscopy and plasmonics.

Journal: Analytica chimica acta

Published: March 23, 2024

Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together.

Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together.

Journal: International journal of molecular sciences

Published: February 01, 2024

GI snapshot: arrhythmia, dysphagia and weight loss in a 71-year-old man.

GI snapshot: arrhythmia, dysphagia and weight loss in a 71-year-old man.

Journal: Gut

Published: January 05, 2024

Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease Treatment.

Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease Treatment.

Journal: Journal of clinical medicine

Published: December 01, 2023

Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.

Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.

Journal: Journal of gastrointestinal and liver diseases : JGLD

Published: June 20, 2023

Showing 1-12 of 14

Last Updated: 09/26/2026